Serial ctDNA monitoring in metastatic breast cancer using an ultrasensitive tumor-informed structural variant-based assay

Tumor-informed circulating tumor DNA identifies high-grade serous ovarian cancer patients at highest risk for recurrence despite optimal first-line treatment with primary macroscopic complete resection

Abstract #518574: Ultrasensitive Structural Variant-based ctDNA detection of MRD in Colorectal Cancer – the CITCCA study

Prevalence and dynamics of circulating tumor DNA among patients with triple-negative breast cancer undergoing preoperative systemic therapy with or without immunotherapy

Neo-N: three-year event-free survival (EFS) and overall survival (OS) and ultrasensitive ctDNA and tumor infiltrating lymphocyte (TIL) dynamics in early triple-negative breast cancer (tnbc) treated with neoadjuvant carboplatin/paclitaxel and nivolumab

CATER-MRD: Capecitabine for Targeted Eradication of aRising ctDNA Molecular Residual Disease in ER+/HER2-negative Breast Cancer

CLAIRE: A Multicenter, Prospective Single-arm Phase II Study Evaluating Liquid Biopsy Guided Intensified Follow-up Surveillance in Patients with Intermediate to High-risk ER+/HER2-negative Early-stage Breast Cancer

Longitudinal ctDNA Tracking in Early and Recurrent Breast Cancer Using an Ultrasensitive Structural Variant-Based Assay: An Updated Analysis from the TRACER Study

NeoCircle: circulating tumor DNA (ctDNA) dynamics during neoadjuvant chemotherapy predicts survival in primary breast cancer

Detecting ctDNA using personalized structural variants to forecast recurrence in localized soft tissue sarcoma (STS)